India

ADD (previously HOLD)

Consensus ratings*: Buy 3	Hold 1	Sell 0
Current price:		Rs470
Target price:		Rs581
Previous target:		Rs698
Up/downside:		23.6%
InCred Research / Consensus:		-10.5%
Reuters:		
Bloomberg:	THYRC	CAR IN
Market cap:	U	S\$343m
	Rs	24,885m
Average daily turnover:	ι	JS\$1.4m
	R	s100.2m
Current shares o/s:		52.9m
Free float: *Source: Bloomberg		28.9%

Key changes in this note

- > FY24F/25F revenue cut by 2.9%/0.3%.
- > FY24F/25F EBITDA raised by 1.8%/11.4%.
- FY24F/25F PAT raised by 12.2%/21.2%.



Promoters Nippon India Small Cap Fund Arisaig Asia Fund

6.4

6.1

Analyst(s)



Rahul AGARWAL T (91) 22 4161 1553 E rahul.agarwal@incredcapital.com Harshit SARAWAGI T (91) 22 4161 0000 E harshit.sarawagi@incredcapital.com

Thyrocare Technologies Ltd.

4Q - In line excl. one-offs, non-cash charges

- 4Q revenue & EBITDA were in line with our estimates, excluding bad debt provision and non-cash ESOP charges. Non-Covid sales up 28% yoy in 4Q.
- New lab openings, NABL accreditations and postal pin code expansion is now complete. Management explores global business to add to growth levers.
- Expect revenue/EBITDA CAGR of 15%/28% over FY23-25F. Stock trades at ~50% discount to mean P/E. Promoter stock pledge key risk. Upgrade to ADD.

4Q in line excluding bad debt provision and non-cash charges

Thyrocare Technologies' (TTL) adj. revenue/EBITDA/PAT in 4QFY23 stood at Rs1.4bn/Rs389m/Rs267m, +4%/+4%/+24% yoy, respectively. Revenue/EBITDA were in line with our estimates while EBITDA was up by 15% vs. Bloomberg consensus estimate. PAT was up by 8%/34% vs. our/Bloomberg consensus estimates, respectively. Diagnostics accounted for 91% of total revenue while imaging was at 9% in 4Q. Consol. adjusted (excl. non-cash API Holding ESOP charge of Rs65m) EBITDA margin was at 23%. Also, if we exclude the bad debt provision of Rs77.9m, adjusted EBITDA margin stood at 28.7%, flat yoy, in 4Q. Non-Covid revenue/sample volume were at Rs1.2bn/5.7m, +18%/20% yoy, respectively, on a weak base. Radiology revenue/EBITDA were at Rs111m/Rs16m, +53%/+3x yoy, respectively, in 4Q. Aarogyam (wellness) accounted for 40% of FY23 total pathology revenue. PharmEasy accounted for 12% of total pathology revenue in FY23. Net cash stood at Rs1.5bn (Mar 2023). FY23 dividend payout was at 93%.

After India business realignment, now exploring global business

TTL achieved most of its stated target on new lab openings, NABL lab accreditations, pin code expansion, higher share of NABL lab reports, and TAT of <24 hours in FY23. Radiology has been fully restructured and two centres to be added in 2HFY24F. In order to boost revenue/EBITDA growth, TTL is exploring African markets for B2B foray in a joint venture with local partners. The capex earmarked is ~Rs100m (~50% share of total JV investment of Rs200m) for FY24F and TTL expects revenue to start from 2HFY24F. Management stated that the global foray will have no negative impact on TTL's margins.

Change in our estimates, valuation and risks

We have rationalized non-Covid samples, added global business and built in operating leverage benefits for FY24F-25F. The CMP implies a ~30% discount to our rolled-forward Mar 2024 NPV of Rs683/share. We built in a lower discount of 15% to NPV as 100% promoter equity stake pledged with lenders has no covenants linked to TTL's stock price and the shares cannot be sold in the open market in case of margin shortfall. Our new TP is Rs581 (Rs698 earlier) implying an exit P/E of 21x FY25F EPS. TTL trades at ~50% discount to its mean P/E of 33-35x since listing. We upgrade TTL's rating to ADD, expecting business recovery in FY24F-25F and a significant valuation discount to the past. Promoter's stock pledge and TTL's weak financial health are big downside risks.

Financial Summary	Mar-21A	Mar-22A	Mar-23A	Mar-24F	Mar-25F
Revenue (Rsm)	4,946	5,889	5,267	5,982	7,072
Operating EBITDA (Rsm)	1,713	2,349	1,390	1,768	2,282
Net Profit (Rsm)	1,131	1,761	644	970	1,390
Core EPS (Rs)	21.4	33.3	14.7	20.3	27.3
Core EPS Growth	22.2%	55.7%	(55.7%)	37.8%	34.2%
FD Core P/E (x)	22.00	14.13	31.88	23.13	17.24
DPS (Rs)	25.0	15.0	18.0	17.5	20.0
Dividend Yield	5.31%	3.19%	3.83%	3.72%	4.25%
EV/EBITDA (x)	13.84	10.01	16.84	13.10	9.92
P/FCFE (x)	46.28	29.48	24.29	20.82	15.62
Net Gearing	(28.1%)	(26.4%)	(28.2%)	(32.7%)	(39.9%)
P/BV (x)	5.83	4.73	4.66	4.62	4.36
ROE	28.5%	36.9%	14.7%	20.1%	26.0%
% Change In Core EPS Estimates				3.40%	14.97%
InCred Research/Consensus EPS (x)					

SOURCE: INCRED RESEARCH, COMPANY REPORTS

4QFY23 earnings-call takeways

- Operations update: TTL now offers a test menu comprising 700+ tests, has 7,400+ active franchisees, is present in 4,600+ pin codes in India and had an average report delivery time of 14 hours at the end of Mar 2023. The company operated 31 labs, of which 20 are NABL-accredited. Nearly 85% of sample testing was processed at NABL labs in 4QFY23. TTL launched a new series of investigative test packages under a new sub-brand Jaanch. These are doctor-curated specialized test packages related to fever, heart, cancer, skin care, etc. The company introduced ThyroNXT a new digital platform for its B2B franchisee partners in 4Q. The franchisee segment accounted for ~60% of non-Covid pathology revenue in 4Q.
- Non-renewal of government contract: A contract with the Municipal Corporation of Greater Mumbai (MCGM) expired in Feb 2023, with a revenue run-rate of Rs120m/year.
- International business: To boost revenue/EBITDA growth, TTL is exploring international geographies to replicate its Indian success in the B2B diagnostics segment. Africa, Mid-East and Southeast Asia are three key markets targeted by TTL. To start with, TTL would have a local presence with the opening of three labs across three locations in Africa, in a joint venture with a local partner. The estimated total investment for the African joint venture is Rs200m. Assuming that TTL would own ~50% equity stake in the joint venture, TTL's share works out to Rs100m that will be invested in 2HFY24F. As per management, international foray will add to revenue growth and is marginaccretive vs. India EBITDA margin.
- **Covid-related government debtors:** As of end-Mar 2023, the total outstanding receivables due from government institutions was Rs600m (gross receivables of Rs850m at the end of Mar 2023), due for over two years now. Of this, bad debt provision to the tune of ~Rs200m has been accounted over FY22 and FY23. Of the Rs600m, Rs510m is due from the Maharashtra government while the remaining Rs90m is due from state governments of Uttarakhand and Jharkhand & also from Bengaluru Municipal Corporation.
- **Nuclear Healthcare:** The PET-CT scan business had 10 operational centres with 13 test machines as of end-Mar 2023. The company plans to add two additional centres in FY24F.
- **Cash flow:** Net working capital cycle was high at 36 days of sales versus longterm average of 10-20 days, largely due to unpaid government receivables. FY23 OCF/FCF stood at Rs1.3bn/Rs878m, respectively. Net cash was at Rs1.5bn as of end-Mar 2023. Dividend payout was at 150% for FY23.

Health Care Providers & Svs | India Thyrocare Technologies Ltd. | May 25, 2023

InCred Equities



Y/E Mar (Rs m)	4QFY23	4QFY22	yoy (%)	3QFY23	qoq (%)	Mar-23	Mar-22	yoy (%)
Revenue	1,359	1,306	4.0	1,280	6.1	5,267	5,889	(10.6
EBITDA	311	376	(17.1)	337	(7.5)	1,390	2,349	(40.8)
EBITDA margin (%)	22.9	28.8	-585 bp	26.3	-339 bp	26.4	39.9	-1,350 bp
Adj. PAT	189	215	(11.9)	205	(7.7)	821	1,763	(53.4)
Diluted EPS (Rs)	3.6	4.1		3.9		15.5	33.3	
				SOLIE	CE: INCRED	RESEARCH	COMPANY	REPORTS

Figure 3: Actuals	vs. our estimates			Figure 4: Actuals vs. Bloomberg consensus estimates				
Rsm	4QFY23	4QFY23F	Var(%)	Rs m	4QFY23	4QFY23C	Var(%)	
Revenue	1,359	1,408	(3.5)	Revenue	1,359	1,362	(0.2)	
EBITDA	311	392	(20.6)	EBITDA	311	338	(7.7)	
EBITDA margin (%)	22.9	27.9	-495 bp	EBITDA margin (%)	22.9	24.8	-186 bp	
Adj. PAT	189	247	(23.3)	Adj. PAT	189	200	(5.3)	
SOURCE: INCRED RESEARCH ESTIMATES, COMPANY REPORTS					SOURCE: INCRED RESEARCH, COMPANY REPORTS, BLOOMBERG			

InCred Equities

Health Care Providers & Svs | India Thyrocare Technologies Ltd. | May 25, 2023


Figure 5: Change in our estimates								
	New estin	nates	Old estim	ates	Change	(%)		
	FY24F	FY25F	FY24F	FY25F	FY24F	FY25F		
Revenue	5,982	7,072	6,158	7,091	-2.9	-0.3		
EBITDA	1,768	2,282	1,737	2,049	1.8	11.4		
Adjusted consol. PAT	1,113	1,463	992	1,207	12.2	21.2		
		SOURCE: I	NCRED RESEA	RCH ESTIMAT	ES, COMPANY	REPORTS		

	FY24F	FY25F	FY26F	FY27F	FY28F	FY29F	FY30F	FY31F	FY32F	FY33F	FY38F
EBIT	1,403	1,887	2,150	2,517	2,889	3,256	3,623	3,983	4,327	4,642	5,913
Depreciation	439	474	505	536	567	599	631	663	695	727	882
Tax paid	(327)	(468)	(546)	(649)	(752)	(851)	(951)	(1,051)	(1,148)	(1,240)	(1,631)
WC changes	252	48	-23	-31	-33	-34	-35	-35	-35	-34	-36
Capex	(350)	(300)	(315)	(331)	(347)	(365)	(383)	(402)	(422)	(443)	(566)
FCFF	1,418	1,640	1,770	2,041	2,324	2,605	2,885	3,158	3,417	3,653	4,562
Discounted FCFF	1,418	1,467	1,416	1,460	1,486	1,490	1,476	1,445	1,398	1,337	955
Discount factor (x)	1.00	0.89	0.80	0.72	0.64	0.57	0.51	0.46	0.41	0.37	0.21
WACC (%)	11.8										
Terminal growth rate (%)	5.0						v	VACC (%)			
Sum of discounted FCFF	19,914				10.8	11.3	11.8	12.3	12.8		
Terminal value	14,726			3.0	698	655	616	582	551		
Enterprise value	34,640			4.0	741	690	645	607	572		
Net debt	(1,765)		Terminal	5.0	798	736	683	638	598		
Lease liabilities	233		growth	6.0	879	800	734	679	632		
Equity value	36,171		rate (%)	7.0	1,003	893	807	736	678		
Number of equity shares o/s. (m)	52.9										
Equity value per share (Rs/sh)	683										

4

Health Care Providers & Svs | India Thyrocare Technologies Ltd. | May 25, 2023

BY THE NUMBERS



(Rs mn)	Mar-21A	Mar-22A	Mar-23A	Mar-24F	Mar-25F
Total Net Revenues	4,946	5,889	5,267	5,982	7,072
Gross Profit	3,307	4,192	3,634	4,128	4,880
Operating EBITDA	1,713	2,349	1,390	1,768	2,282
Depreciation And Amortisation	(303)	(339)	(387)	(439)	(474
Operating EBIT	1,410	2,010	1,003	1,328	1,808
Financial Income/(Expense)	36	(17)	(11)	26	34
Pretax Income/(Loss) from Assoc.	(1)	(2)	12	10	11
Non-Operating Income/(Expense)	80	285	71	75	78
Profit Before Tax (pre-El)	1,525	2,277	1,075	1,440	1,931
Exceptional Items			(189)	(143)	(74)
Pre-tax Profit	1,525	2,277	886	1,297	1,858
Taxation	(393)	(516)	(242)	(327)	(468
Exceptional Income - post-tax					
Profit After Tax	1,131	1,761	644	970	1,390
Minority Interests					
Preferred Dividends					
FX Gain/(Loss) - post tax					
Other Adjustments - post-tax					
Net Profit	1,131	1,761	644	970	1,390
Recurring Net Profit	1,131	1,761	781	1,077	1,445
Fully Diluted Recurring Net Profit	1,131	1,761	781	1,077	1,445

Cash Flow					
(Rs mn)	Mar-21A	Mar-22A	Mar-23A	Mar-24F	Mar-25F
EBITDA	1,713	2,349	1,390	1,768	2,282
Cash Flow from Invt. & Assoc.					
Change In Working Capital	(176)	(792)	58	252	48
(Incr)/Decr in Total Provisions					
Other Non-Cash (Income)/Expense	(49)	(117)	272	(148)	(80)
Other Operating Cashflow	80	285	71	75	78
Net Interest (Paid)/Received	(9)	(24)	(24)	(23)	(27)
Tax Paid	(432)	(568)	(285)	(327)	(468)
Cashflow From Operations	1,126	1,134	1,483	1,597	1,833
Capex	(187)	(149)	(416)	(350)	(300)
Disposals Of FAs/subsidiaries					
Acq. Of Subsidiaries/investments					
Other Investing Cashflow	(315)	(87)	26	(51)	61
Cash Flow From Investing	(502)	(236)	(390)	(401)	(239)
Debt Raised/(repaid)	(86)	(54)	(68)		
Proceeds From Issue Of Shares					
Shares Repurchased					
Dividends Paid	(528)	(793)	(794)	(926)	(1,059)
Preferred Dividends					
Other Financing Cashflow	(1)	(48)		(23)	(27)
Cash Flow From Financing	(616)	(894)	(862)	(949)	(1,085)
Total Cash Generated	8	4	231	247	509
Free Cashflow To Equity	538	845	1,025	1,196	1,594
Free Cashflow To Firm	633	922	1,117	1,219	1,621

SOURCES: INCRED RESEARCH, COMPANY REPORTS

Health Care Providers & Svs | India Thyrocare Technologies Ltd. | May 25, 2023

BY THE NUMBERS...cont'd

(Rs mn)	Mar-21A	Mar-22A	Mar-23A	Mar-24F	Mar-25
Total Cash And Equivalents	1,202	1,391	1,508	1,765	2,28
Total Debtors	447	932	851	574	38
Inventories	234	245	277	328	38
Total Other Current Assets	95	132	94	107	12
Total Current Assets	1,978	2,700	2,729	2,773	3,18
Fixed Assets	1,705	1,496	1,582	1,522	1,38
Total Investments	211	209	221	321	32
Intangible Assets	1,003	1,003	1,003	1,003	1,00
Total Other Non-Current Assets	516	663	792	791	79
Total Non-current Assets	3,435	3,370	3,598	3,637	3,49
Short-term Debt					
Current Portion of Long-Term Debt					
Total Creditors	250	166	254	246	29
Other Current Liabilities	670	430	446	492	38
Total Current Liabilities	920	595	699	738	67
Total Long-term Debt					
Hybrid Debt - Debt Component					
Total Other Non-Current Liabilities	221	210	266	266	26
Total Non-current Liabilities	221	210	266	266	26
Total Provisions			10	10	1
Total Liabilities	1,140	805	975	1,013	95
Shareholders Equity	4,273	5,266	5,343	5,387	5,71
Minority Interests			9	9	
· ·	4,273	5,266	9 5,352	9 5,396	5,72
Minority Interests Total Equity	4,273 Mar-21A	5,266 Mar-22A	0		5,72
Minority Interests Total Equity		,	5,352	5,396	5,72 Mar-25
Minority Interests Total Equity Key Ratios	Mar-21A	Mar-22A	5,352 Mar-23A	5,396 Mar-24F	5,72 Mar-25 18.29
Minority Interests Total Equity Key Ratios Revenue Growth	Mar-21A 14.2%	Mar-22A 19.1%	5,352 Mar-23A (10.6%)	5,396 Mar-24F 13.6%	5,72 Mar-25 18.2 29.1
Minority Interests Total Equity Key Ratios Revenue Growth Operating EBITDA Growth	Mar-21A 14.2% (0.7%)	Mar-22A 19.1% 37.2%	5,352 Mar-23A (10.6%) (40.8%)	5,396 Mar-24F 13.6% 27.2%	5,72 Mar-25 18.2° 29.1° 32.3° 43.1
Minority Interests Total Equity Key Ratios Revenue Growth Operating EBITDA Growth Operating EBITDA Margin	Mar-21A 14.2% (0.7%) 34.6%	Mar-22A 19.1% 37.2% 39.9%	5,352 Mar-23A (10.6%) (40.8%) 26.4%	5,396 Mar-24F 13.6% 27.2% 29.5%	5,72 Mar-25 18.2° 29.1° 32.3° 43.1
Minority Interests Total Equity Key Ratios Revenue Growth Operating EBITDA Growth Operating EBITDA Margin Net Cash Per Share (Rs)	Mar-21A 14.2% (0.7%) 34.6% 22.70	Mar-22A 19.1% 37.2% 39.9% 26.27	5,352 Mar-23A (10.6%) (40.8%) 26.4% 28.47	5,396 Mar-24F 13.6% 27.2% 29.5% 33.31	5,72 Mar-25 18.29 29.19 32.39 43.1 107.9
Minority Interests Total Equity Key Ratios Revenue Growth Operating EBITDA Growth Operating EBITDA Margin Net Cash Per Share (Rs) BVPS (Rs)	Mar-21A 14.2% (0.7%) 34.6% 22.70 80.69	Mar-22A 19.1% 37.2% 39.9% 26.27 99.44	5,352 Mar-23A (10.6%) (40.8%) 26.4% 28.47 100.90	5,396 Mar-24F 13.6% 27.2% 29.5% 33.31 101.68	5,72 Mar-25 18.2 ² 29.1 ⁴ 32.3 ³ 43.1 107.9 68.0
Minority Interests Total Equity Key Ratios Revenue Growth Operating EBITDA Growth Operating EBITDA Margin Net Cash Per Share (Rs) BVPS (Rs) Gross Interest Cover	Mar-21A 14.2% (0.7%) 34.6% 22.70 80.69 162.03	Mar-22A 19.1% 37.2% 39.9% 26.27 99.44 84.82 22.7% 45.0%	5,352 Mar-23A (10.6%) (40.8%) 26.4% 28.47 100.90 42.66	5,396 Mar-24F 13.6% 27.2% 29.5% 33.31 101.68 58.65	5,72 Mar-25 18.2 ² 29.1 ¹ 32.3 ³ 43.1 107.9 68.0 25.2 ⁴
Minority Interests Total Equity Key Ratios Revenue Growth Operating EBITDA Growth Operating EBITDA Margin Net Cash Per Share (Rs) BVPS (Rs) Gross Interest Cover Effective Tax Rate Net Dividend Payout Ratio Accounts Receivables Days	Mar-21A 14.2% (0.7%) 34.6% 22.70 80.69 162.03 25.8% 116.8% 22.60	Mar-22A 19.1% 37.2% 39.9% 26.27 99.44 84.82 22.7% 45.0% 42.73	5,352 Mar-23A (10.6%) (40.8%) 26.4% 28.47 100.90 42.66 27.4% 148.0% 61.79	5,396 Mar-24F 13.6% 27.2% 29.5% 33.31 101.68 58.65 25.2% 95.4% 43.47	5,72 Mar-25 18.2 ^c 29.1 ^c 32.3 ^c 43.1 107.9 68.0 25.2 ^c 76.0 ^c 24.8
Minority Interests Total Equity Key Ratios Revenue Growth Operating EBITDA Growth Operating EBITDA Margin Net Cash Per Share (Rs) BVPS (Rs) Gross Interest Cover Effective Tax Rate Net Dividend Payout Ratio Accounts Receivables Days Inventory Days	Mar-21A 14.2% (0.7%) 34.6% 22.70 80.69 162.03 25.8% 116.8%	Mar-22A 19.1% 37.2% 39.9% 26.27 99.44 84.82 22.7% 45.0%	5,352 Mar-23A (10.6%) (40.8%) 26.4% 28.47 100.90 42.66 27.4% 148.0%	5,396 Mar-24F 13.6% 27.2% 29.5% 33.31 101.68 58.65 25.2% 95.4%	5,72 Mar-25 18.2 29.1 32.3 43.1 107.9 68.0 25.2 76.0 24.8 59.5
Minority Interests Total Equity Key Ratios Revenue Growth Operating EBITDA Growth Operating EBITDA Margin Net Cash Per Share (Rs) BVPS (Rs) Gross Interest Cover Effective Tax Rate Net Dividend Payout Ratio Accounts Receivables Days Inventory Days Accounts Payables Days	Mar-21A 14.2% (0.7%) 34.6% 22.70 80.69 162.03 25.8% 116.8% 22.60 48.97 52.19	Mar-22A 19.1% 37.2% 39.9% 26.27 99.44 84.82 22.7% 45.0% 42.73 51.51 44.72	5,352 Mar-23A (10.6%) (40.8%) 26.4% 28.47 100.90 42.66 27.4% 148.0% 61.79 58.36 46.87	5,396 Mar-24F 13.6% 27.2% 29.5% 33.31 101.68 58.65 25.2% 95.4% 43.47 59.49 49.14	5,72 Mar-25 18.2 ^c 29.1 ^c 32.3 ^c 43.1 107.9 68.0 25.2 ^c 76.0 ^c 24.8 59.5 44.6
Minority Interests Total Equity Key Ratios Revenue Growth Operating EBITDA Growth Operating EBITDA Margin Net Cash Per Share (Rs) BVPS (Rs) Gross Interest Cover Effective Tax Rate Net Dividend Payout Ratio Accounts Receivables Days Inventory Days	Mar-21A 14.2% (0.7%) 34.6% 22.70 80.69 162.03 25.8% 116.8% 22.60 48.97	Mar-22A 19.1% 37.2% 39.9% 26.27 99.44 84.82 22.7% 45.0% 42.73 51.51	5,352 Mar-23A (10.6%) (40.8%) 26.4% 28.47 100.90 42.66 27.4% 148.0% 61.79 58.36	5,396 Mar-24F 13.6% 27.2% 29.5% 33.31 101.68 58.65 25.2% 95.4% 43.47 59.49	5,72 Mar-25 18.2 ^c 29.1 ^c 32.3 ^c 43.1 107.9 68.0 25.2 ^c 76.0 ^c 24.8 59.5 44.6
Minority Interests Total Equity Key Ratios Revenue Growth Operating EBITDA Growth Operating EBITDA Margin Net Cash Per Share (Rs) BVPS (Rs) Gross Interest Cover Effective Tax Rate Net Dividend Payout Ratio Accounts Receivables Days Inventory Days Accounts Payables Days ROIC (%) ROCE (%)	Mar-21A 14.2% (0.7%) 34.6% 22.70 80.69 162.03 25.8% 116.8% 22.60 48.97 52.19 48.6% 36.3%	Mar-22A 19.1% 37.2% 39.9% 26.27 99.44 84.82 22.7% 45.0% 42.73 51.51 44.72 65.3% 42.3%	5,352 Mar-23A (10.6%) (40.8%) 26.4% 28.47 100.90 42.66 27.4% 148.0% 61.79 58.36 46.87 25.9% 19.1%	5,396 Mar-24F 13.6% 27.2% 29.5% 33.31 101.68 58.65 25.2% 95.4% 43.47 59.49 49.14 34.1% 25.6%	5,72 Mar-25 18.2 29.1 32.3 43.1 107.9 68.0 25.2 76.0 24.8 59.5 44.6 50.4 33.5
Minority Interests Total Equity Key Ratios Revenue Growth Operating EBITDA Growth Operating EBITDA Margin Net Cash Per Share (Rs) BVPS (Rs) Gross Interest Cover Effective Tax Rate Net Dividend Payout Ratio Accounts Receivables Days Inventory Days Accounts Payables Days ROIC (%)	Mar-21A 14.2% (0.7%) 34.6% 22.70 80.69 162.03 25.8% 116.8% 22.60 48.97 52.19 48.6%	Mar-22A 19.1% 37.2% 39.9% 26.27 99.44 84.82 22.7% 45.0% 42.73 51.51 44.72 65.3%	5,352 Mar-23A (10.6%) (40.8%) 26.4% 28.47 100.90 42.66 27.4% 148.0% 61.79 58.36 46.87 25.9%	5,396 Mar-24F 13.6% 27.2% 29.5% 33.31 101.68 58.65 25.2% 95.4% 43.47 59.49 49.14 34.1%	5,72 Mar-25 18.2 29.1 32.3 43.1 107.9 68.0 25.2 76.0 24.8 59.5 44.6 50.4 33.5
Minority Interests Total Equity Key Ratios Revenue Growth Operating EBITDA Growth Operating EBITDA Margin Net Cash Per Share (Rs) BVPS (Rs) Gross Interest Cover Effective Tax Rate Net Dividend Payout Ratio Accounts Receivables Days Inventory Days Accounts Payables Days ROIC (%) ROCE (%) Return On Average Assets	Mar-21A 14.2% (0.7%) 34.6% 22.70 80.69 162.03 25.8% 116.8% 22.60 48.97 52.19 48.6% 36.3%	Mar-22A 19.1% 37.2% 39.9% 26.27 99.44 84.82 22.7% 45.0% 42.73 51.51 44.72 65.3% 42.3%	5,352 Mar-23A (10.6%) (40.8%) 26.4% 28.47 100.90 42.66 27.4% 148.0% 61.79 58.36 46.87 25.9% 19.1%	5,396 Mar-24F 13.6% 27.2% 29.5% 33.31 101.68 58.65 25.2% 95.4% 43.47 59.49 49.14 34.1% 25.6%	5,72 Mar-25 18.2 29.1 32.3 43.1 107.9 68.0 25.2 76.0 24.8 59.5 44.6 50.4 33.5
Minority Interests Total Equity Key Ratios Revenue Growth Operating EBITDA Growth Operating EBITDA Margin Net Cash Per Share (Rs) BVPS (Rs) Gross Interest Cover Effective Tax Rate Net Dividend Payout Ratio Accounts Receivables Days Inventory Days Accounts Payables Days ROIC (%) ROCE (%)	Mar-21A 14.2% (0.7%) 34.6% 22.70 80.69 162.03 25.8% 116.8% 22.60 48.97 52.19 48.6% 36.3% 21.7%	Mar-22A 19.1% 37.2% 39.9% 26.27 99.44 84.82 22.7% 45.0% 42.73 51.51 44.72 65.3% 42.3% 31.0%	5,352 Mar-23A (10.6%) (40.8%) 26.4% 28.47 100.90 42.66 27.4% 148.0% 61.79 58.36 46.87 25.9% 19.1% 10.6%	5,396 Mar-24F 13.6% 27.2% 29.5% 33.31 101.68 58.65 25.2% 95.4% 43.47 59.49 49.14 34.1% 25.6% 14.8%	Mar-25 18.22 29.19 32.39 43.1 107.9 68.0 25.29 76.09 24.8 59.5 44.6 50.49 33.59 20.69
Minority Interests Total Equity Key Ratios Revenue Growth Operating EBITDA Growth Operating EBITDA Margin Net Cash Per Share (Rs) BVPS (Rs) Gross Interest Cover Effective Tax Rate Net Dividend Payout Ratio Accounts Receivables Days Inventory Days Accounts Payables Days ROIC (%) ROCE (%) Return On Average Assets Key Drivers	Mar-21A 14.2% (0.7%) 34.6% 22.70 80.69 162.03 25.8% 116.8% 22.60 48.97 52.19 48.6% 36.3% 21.7%	Mar-22A 19.1% 37.2% 39.9% 26.27 99.44 84.82 22.7% 45.0% 42.73 51.51 44.72 65.3% 42.3% 31.0% Mar-22A	5,352 Mar-23A (10.6%) (40.8%) 26.4% 28.47 100.90 42.66 27.4% 148.0% 61.79 58.36 46.87 25.9% 19.1% 10.6% Mar-23A	5,396 Mar-24F 13.6% 27.2% 29.5% 33.31 101.68 58.65 25.2% 95.4% 43.47 59.49 49.14 34.1% 25.6% 14.8% Mar-24F	5,72 Mar-25 18.22 29.11 32.33 43.1 107.9 68.0 25.24 76.00 24.8 59.5 44.6 50.44 33.55 20.66 Mar-25
Minority Interests Total Equity Key Ratios Revenue Growth Operating EBITDA Growth Operating EBITDA Margin Net Cash Per Share (Rs) BVPS (Rs) Gross Interest Cover Effective Tax Rate Net Dividend Payout Ratio Accounts Receivables Days Inventory Days Accounts Payables Days ROIC (%) ROCE (%) Return On Average Assets Key Drivers Samples processed (mn nos)	Mar-21A 14.2% (0.7%) 34.6% 22.70 80.69 162.03 25.8% 116.8% 22.60 48.97 52.19 48.6% 36.3% 21.7% Mar-21A 17	Mar-22A 19.1% 37.2% 39.9% 26.27 99.44 84.82 22.7% 45.0% 42.73 51.51 44.72 65.3% 42.3% 31.0% Mar-22A 21	5,352 Mar-23A (10.6%) (40.8%) 26.4% 28.47 100.90 42.66 27.4% 148.0% 61.79 58.36 46.87 25.9% 19.1% 10.6% Mar-23A 15	5,396 Mar-24F 13,6% 27.2% 29.5% 33,31 101.68 58.65 25.2% 95.4% 43,47 59.49 49.14 34.1% 25.6% 14.8% Mar-24F 26	5,72 Mar-25 18.2° 29.1° 32.3° 43.1 107.9 68.0 25.2° 76.0° 24.8 59.5 44.6 50.4° 33.5° 20.6° 20.6° Mar-25 2
Minority Interests Total Equity Key Ratios Revenue Growth Operating EBITDA Growth Operating EBITDA Margin Net Cash Per Share (Rs) BVPS (Rs) Gross Interest Cover Effective Tax Rate Net Dividend Payout Ratio Accounts Receivables Days Inventory Days Accounts Payables Days ROIC (%) ROCE (%) Return On Average Assets Key Drivers	Mar-21A 14.2% (0.7%) 34.6% 22.70 80.69 162.03 25.8% 116.8% 22.60 48.97 52.19 48.6% 36.3% 21.7%	Mar-22A 19.1% 37.2% 39.9% 26.27 99.44 84.82 22.7% 45.0% 42.73 51.51 44.72 65.3% 42.3% 31.0% Mar-22A	5,352 Mar-23A (10.6%) (40.8%) 26.4% 28.47 100.90 42.66 27.4% 148.0% 61.79 58.36 46.87 25.9% 19.1% 10.6% Mar-23A	5,396 Mar-24F 13.6% 27.2% 29.5% 33.31 101.68 58.65 25.2% 95.4% 43.47 59.49 49.14 34.1% 25.6% 14.8% Mar-24F	Mar-25 18.22 29.19 32.39 43.1 107.9 68.0 25.29 76.09 24.8 59.5 44.6 50.49 33.59 20.69 Mar-25

SOURCES: INCRED RESEARCH, COMPANY REPORTS

DISCLAIMER

This report (including the views and opinions expressed therein, and the information comprised therein) has been prepared by Incred Research Services Private Ltd.(formerly known as Earnest Innovation Partners Private Limited) (hereinafter referred to as "IRSPL"). IRSPL is registered with SEBI as a Research Analyst vide Registration No. INH000011024. Pursuant to a trademark agreement, IRSPL has adopted "Incred Equities" as its trademark for use in this report.

The term "IRSPL" shall, unless the context otherwise requires, mean IRSPL and its affiliates, subsidiaries and related companies. This report is not directed or intended for distribution to or use by any person or entity resident in a state, country or any jurisdiction, where such distribution, publication, availability or use would be contrary to law, regulation or which would subject IRSPL and its affiliates/group companies to registration or licensing requirements within such jurisdictions.

This report is being supplied to you strictly on the basis that it will remain confidential. No part of this report may be (i) copied, photocopied, duplicated, stored or reproduced in any form by any means; or (ii) redistributed or passed on, directly or indirectly, to any other person in whole or in part, for any purpose without the prior written consent of IRSPL.

The information contained in this report is prepared from data believed to be correct and reliable at the time of issue of this report.

IRSPL is not required to issue regular reports on the subject matter of this report at any frequency and it may cease to do so or change the periodicity of reports at any time. IRSPL is not under any obligation to update this report in the event of a material change to the information contained in this report. IRSPL has not any and will not accept any, obligation to (i) check or ensure that the contents of this report remain current, reliable or relevant; (ii) ensure that the content of this report constitutes all the information a prospective investor may require; (iii) ensure the adequacy, accuracy, completeness, reliability or fairness of any views, opinions and information, and accordingly, IRSPL and its affiliates/group companies (and their respective directors, associates, connected persons and/or employees) shall not be liable in any manner whatsoever for any consequences (including but not limited to any direct, indirect or consequential losses, loss of profits and damages) of any reliance thereon or usage thereof.

Unless otherwise specified, this report is based upon reasonable sources. Such sources will, unless otherwise specified, for market data, be market data and prices available from the main stock exchange or market where the relevant security is listed, or, where appropriate, any other market. Information on the accounts and business of company(ies) will generally be based on published statements of the company(ies), information disseminated by regulatory information services, other publicly available information and information resulting from our research. Whilst every effort is made to ensure that statements of facts made in this report are accurate, all estimates, projections, forecasts, expressions of opinion and other subjective judgments contained in this report are based on assumptions considered to be reasonable as of the date of the document in which they are contained and must not be construed as a representation that the matters referred to therein will occur. Past performance is not a reliable indicator of future performance. The value of investments may go down as well as up and those investing may, depending on the investments in question, lose more than the initial investment. No report shall constitute an offer or an invitation by or on behalf of IRSPL and its affiliates/group companies to any person to buy or sell any investments.

The opinions expressed are based on information which are believed to be accurate and complete and obtained through reliable public or other nonconfidential sources at the time made. (Information barriers and other arrangements may be established where necessary to prevent conflicts of interests arising. However, the analyst(s) may receive compensation that is based on his/their coverage of company(ies) in the performance of his/their duties or the performance of his/their recommendations. In reviewing this report, an investor should be aware that any or all of the foregoing, among other things, may give rise to real or potential conflicts of interest. Additional information is, subject to the duties of confidentiality, available on request. The report is not a "prospectus" as defined under Indian Law, including the Companies Act, 2013, and is not, and shall not be, approved by, or filed or registered with, any Indian regulator, including any Registrar of Companies in India, SEBI, any Indian stock exchange, or the Reserve Bank of India. No offer, or invitation to offer, or solicitation of subscription with respect to any such securities listed or proposed to be listed in India is being made, or intended to be made, to the public, or to any member or section of the public in India, through or pursuant to this report.

The research analysts, strategists or economists principally responsible for the preparation of this research report are segregated from the other activities of IRSPL. Information barriers and other arrangements have been established, as required, to prevent any conflicts of interests.

The research analysts, strategists or economists principally responsible for the preparation of this research report are segregated from the other activities of IRSPL. Information barriers and other arrangements have been established, as required, to prevent any conflicts of interests.

IRSPL may have issued other reports (based on technical analysis, event specific, short term views etc.) that are inconsistent with and reach different conclusion from the information presented in this report.

Holding of Analysts/Relatives of Analysts, IRSPL and Associates of IRSPL in the covered securities, as on the date of publishing of this report

InCred Equities

Health Care Providers & Svs | India Thyrocare Technologies Ltd. | May 25, 2023

	Analyst/ Relative	Entity/ Associates
any financial interests in the company covered in this report (subject company) and nature of such financial interest	NO	NO
actual/beneficial ownership of 1% or more in securities of the subject company at the end of the month immediately preceding the date of publication of the research report or date of the public appearance;	NO	NO
any other material conflict of interest at the time of publication of the research report or at the time of public appearance	NO	NO
received any compensation from the subject company in the past twelve months for investment banking or merchant banking or brokerage services or investment advisory or depository or distribution from the subject company in the last twelve months for products/services other than investment banking or merchant banking or broker- age services or investment advisory or depository or distribution from the subject company in the last twelve months	NO	NO
managed or co-managed public offering of securities for the subject company in the last twelve months	NO	NO
received any compensation or other benefits from the subject company or third party in connection with the research report	NO	NO
served as an officer, director or employee of the subject company	NO	NO
been engaged in market making activity for the subject company	NO	NO

Analyst declaration

- The analyst responsible for the production of this report hereby certifies that the views expressed herein accurately and exclusively reflect his or her personal views and opinions about any and all of the issuers or securities analysed in this report and were prepared independently and autonomously in an unbiased manner.
- No part of the compensation of the analyst(s) was, is, or will be directly or indirectly related to the inclusion of specific recommendations(s) or view(s) in this report or based any specific investment banking transaction.
- The analyst(s) has(have) not had any serious disciplinary action taken against him/her(them).
- The analyst, strategist, or economist does not have any material conflict of interest at the time of publication of this report.
- The analyst(s) has(have) received compensation based upon various factors, including quality, accuracy and value of research, overall firm performance, client feedback and competitive factors.

IRSPL and/or its affiliates and/or its Directors/employees may own or have positions in securities of the company(ies) covered in this report or any securities related thereto and may from time to time add to or dispose of, or may be materially interested in, any such securities.

IRSPL and/or its affiliates and/or its Directors/employees may do and seek to do business with the company(ies) covered in this research report and may from time to time (a) buy/sell the securities covered in this report, from time to time and/or (b) act as market maker or have assumed an underwriting commitment in securities of such company(ies), and/or (c) may sell them to or buy them from customers on a principal basis and/or (d) may also perform or seek to perform significant investment banking, advisory, underwriting or placement services for or relating to such company(ies) and/or (e) solicit such investment, advisory or other services from any entity mentioned in thisreport and/or (f) act as a lender/borrower to such company and may earn brokerage or other compensation. However, Analysts are forbidden to acquire, on their own account or hold securities (physical or uncertificated, including derivatives) of companies in respect of which they are compiling and producing financial recommendations or in the result of which they play a key part.